Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H11ClO4 |
Molecular Weight | 254.666 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(OC(=O)C=C1OC)[C@H](O)C2=C(Cl)C=CC=C2
InChI
InChIKey=ICDNYWJQGWNLFP-VXGBXAGGSA-N
InChI=1S/C12H11ClO4/c1-16-9-6-10(14)17-12(9)11(15)7-4-2-3-5-8(7)13/h2-6,11-12,15H,1H3/t11-,12-/m1/s1
Molecular Formula | C12H11ClO4 |
Molecular Weight | 254.666 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Losigamone possesses an unique anticonvulsant activity profile and has an excellent tolerability. Losigamone causes dose-dependent inhibition of the tonic hind leg extension produced by electric shock, pentylenetetrazole, bicuculline, nicotine and 4-aminopyridine. Losigamone also inhibits clonic seizures induced by pentylenetetrazole, bicuculline and picrotoxin, whereas it has no effect on the hind leg extension caused by strychnine and picrotoxin or the clonic seizures induced by NMDA. Losigamone had been in phase III clinical trial for the treatment of partial epilepsies. However, this development was discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Future prospects for the drug treatment of epilepsy. | 2001 |
|
Losigamone add-on therapy in partial epilepsy: a placebo-controlled study. | 2001 Apr |
|
The antiepileptic drug losigamone decreases the persistent Na+ current in rat hippocampal neurons. | 2001 Nov 30 |
|
Perspectives of losigamone in epilepsy treatment. | 2003 Sep-Oct |
|
Voltage gated ion channels: targets for anticonvulsant drugs. | 2005 |
|
Isobolographic analysis of interactions among losigamone analog AO-620 and two conventional antiepileptic drugs. | 2005 Mar-Apr |
|
Interactions between two enantiomers of losigamone and conventional antiepileptic drugs in the mouse maximal electroshock model--an isobolographic analysis. | 2007 Jul 12 |
|
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. | 2009 Mar-Apr |
|
Epilepsy (partial). | 2010 Jun 28 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29355908
750 mg/day in the first two days after randomization and then maintained at 1500 mg/day from the third day for the eight weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:56:16 UTC 2023
by
admin
on
Fri Dec 15 15:56:16 UTC 2023
|
Record UNII |
84R8O3QM2G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID20869555
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
CHEMBL2106442
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
84R8O3QM2G
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
C065427
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
6423
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
SUB08594MIG
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
100000082036
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
LOSIGAMONE
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
10131269
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
C90707
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY | |||
|
112856-44-7
Created by
admin on Fri Dec 15 15:56:16 UTC 2023 , Edited by admin on Fri Dec 15 15:56:16 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |